JP2020520889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520889A5 JP2020520889A5 JP2019550138A JP2019550138A JP2020520889A5 JP 2020520889 A5 JP2020520889 A5 JP 2020520889A5 JP 2019550138 A JP2019550138 A JP 2019550138A JP 2019550138 A JP2019550138 A JP 2019550138A JP 2020520889 A5 JP2020520889 A5 JP 2020520889A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- inhibitors
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078735A JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
| JP2025113816A JP2025138849A (ja) | 2017-03-13 | 2025-07-04 | プリナブリン組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470802P | 2017-03-13 | 2017-03-13 | |
| US62/470,802 | 2017-03-13 | ||
| US201862621528P | 2018-01-24 | 2018-01-24 | |
| US62/621,528 | 2018-01-24 | ||
| PCT/US2018/022064 WO2018169887A1 (en) | 2017-03-13 | 2018-03-12 | Compositions of plinabulin and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078735A Division JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520889A JP2020520889A (ja) | 2020-07-16 |
| JP2020520889A5 true JP2020520889A5 (https=) | 2021-04-22 |
| JP7280192B2 JP7280192B2 (ja) | 2023-05-23 |
Family
ID=63522552
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550138A Active JP7280192B2 (ja) | 2017-03-13 | 2018-03-12 | プリナブリン組成物及びその使用 |
| JP2023078735A Pending JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
| JP2025113816A Pending JP2025138849A (ja) | 2017-03-13 | 2025-07-04 | プリナブリン組成物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078735A Pending JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
| JP2025113816A Pending JP2025138849A (ja) | 2017-03-13 | 2025-07-04 | プリナブリン組成物及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200129504A1 (https=) |
| EP (2) | EP3595653B1 (https=) |
| JP (3) | JP7280192B2 (https=) |
| KR (1) | KR102659907B1 (https=) |
| CN (1) | CN110603037A (https=) |
| AU (2) | AU2018236168B2 (https=) |
| BR (1) | BR112019018880A2 (https=) |
| CA (1) | CA3056077A1 (https=) |
| DK (1) | DK3595653T3 (https=) |
| ES (1) | ES2942889T3 (https=) |
| NZ (2) | NZ778329A (https=) |
| SG (1) | SG11201908420WA (https=) |
| WO (1) | WO2018169887A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249051A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗脑肿瘤的方法 |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| GB201713760D0 (en) * | 2017-08-28 | 2017-10-11 | Univ Leuven Kath | Treatment of epilepsy |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| ES3060133T3 (en) * | 2018-06-01 | 2026-03-25 | Beyondspring Pharmaceuticals Inc | Composition and method of treating cancer associated with egfr mutation |
| GB201913988D0 (en) * | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| EP4045046A4 (en) * | 2019-10-15 | 2024-01-10 | Beyondspring Pharmaceuticals Inc. | Methods and compositions for treating iron disorders |
| KR20230006568A (ko) * | 2020-05-04 | 2023-01-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법 |
| KR102428863B1 (ko) * | 2020-08-11 | 2022-08-03 | 서울대학교병원 | 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| AU2023219702A1 (en) * | 2022-02-10 | 2024-09-05 | Beyondspring Pharmaceuticals, Inc. | Stable plinabulin formulations and methods of their preparation and use |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| BR0313363A (pt) * | 2002-08-02 | 2005-08-09 | Nereus Pharmaceuticals Inc | Deidrofenilahistinas e seus análogos, e sua sìntese |
| US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| EP1711487A1 (en) * | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| EP1926724A1 (en) * | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| JP6311097B2 (ja) * | 2013-07-31 | 2018-04-18 | 学校法人東京薬科大学 | 微小管脱重合剤 |
| JP6411523B2 (ja) * | 2013-10-11 | 2018-10-24 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| AU2016219204B2 (en) * | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
| WO2017139231A1 (en) * | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
-
2018
- 2018-03-12 AU AU2018236168A patent/AU2018236168B2/en active Active
- 2018-03-12 SG SG11201908420W patent/SG11201908420WA/en unknown
- 2018-03-12 EP EP18768238.0A patent/EP3595653B1/en active Active
- 2018-03-12 NZ NZ778329A patent/NZ778329A/en unknown
- 2018-03-12 NZ NZ757213A patent/NZ757213A/en unknown
- 2018-03-12 CN CN201880029191.0A patent/CN110603037A/zh active Pending
- 2018-03-12 EP EP23153650.9A patent/EP4190326A1/en not_active Withdrawn
- 2018-03-12 WO PCT/US2018/022064 patent/WO2018169887A1/en not_active Ceased
- 2018-03-12 ES ES18768238T patent/ES2942889T3/es active Active
- 2018-03-12 US US16/493,271 patent/US20200129504A1/en not_active Abandoned
- 2018-03-12 CA CA3056077A patent/CA3056077A1/en active Pending
- 2018-03-12 KR KR1020197029387A patent/KR102659907B1/ko active Active
- 2018-03-12 JP JP2019550138A patent/JP7280192B2/ja active Active
- 2018-03-12 BR BR112019018880A patent/BR112019018880A2/pt active Search and Examination
- 2018-03-12 DK DK18768238.0T patent/DK3595653T3/da active
-
2023
- 2023-05-11 JP JP2023078735A patent/JP2023099217A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200709A patent/AU2024200709A1/en not_active Abandoned
-
2025
- 2025-07-04 JP JP2025113816A patent/JP2025138849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520889A5 (https=) | ||
| Venning et al. | British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012 | |
| JP5456658B2 (ja) | 抗体製剤 | |
| Jasiak et al. | Immunosuppression in solid-organ transplantation: essentials and practical tips | |
| JP7472122B2 (ja) | コルチコステロイドを投与する方法 | |
| Lee et al. | A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I | |
| US11976113B2 (en) | Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins | |
| JP2014040424A (ja) | 抗体製剤 | |
| JP2022507103A5 (https=) | ||
| TW202327654A (zh) | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 | |
| TWI877239B (zh) | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| CN114502241A (zh) | 抗半乳凝素-9抗体和化疗剂的联合癌症疗法 | |
| CN120501855A (zh) | 给予抗cd38抗体以治疗多发性骨髓瘤的方法 | |
| Thomas et al. | Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis | |
| JP7286665B2 (ja) | ＩｇＥ介在アレルギー性疾患の治療 | |
| Cansu et al. | Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review | |
| CA3239667A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp | |
| KR20240121771A (ko) | 항-tigit 항체의 임상 제제 | |
| CN113453759A (zh) | 治疗巨细胞动脉炎 | |
| EP4267184B1 (en) | Interleukin 5 binding protein dosage regimen | |
| US20230158033A1 (en) | Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | |
| Furfaro et al. | Emerging therapeutic targets and strategies in Crohn’s disease | |
| AU2021376374A1 (en) | Use of isatuximab for the treatment of multiple myeloma | |
| Kaplan et al. | Corticotrophins, corticosteroids, and prostaglandins |